Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.43 |
| ▸ | VCP | P55072 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601444 | 0.80 | VCP (0.46) | VCPKMT2AMEN1MAPTMAOB | |
| SCHEMBL16127874 | 0.78 | GRM4 (0.63) | GRM4KMT2AMEN1MAPT | |
| SCHEMBL3588744 | 0.77 | MAOB (0.55) | VCPKMT2AMEN1MAPTMAOA | |
| SCHEMBL3601281 | 0.76 | LRRK2 (0.43) | LRRK2VCPMAPT | |
| SCHEMBL17531737 | 0.75 | GRM4 (0.63) | GRM4KMT2AMEN1MAPT | |
| SCHEMBL21844863 | 0.73 | KCNK3 (0.61) | GRM4KMT2AMEN1RXFP1 | |
| SCHEMBL20459126 | 0.72 | GRM4 (0.53) | GRM4LRRK2KMT2AMEN1 | |
| SCHEMBL21408403 | 0.71 | GRM4 (0.52) | GRM4LRRK2 | |
| SCHEMBL30093989 | 0.71 | GRM4 (0.52) | GRM4LRRK2 | |
| SCHEMBL3595864 | 0.71 | VCP (0.50) | VCPKMT2AMEN1MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048579-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISTS | ARISTA LUCA | 2010-02-25 | — | — | US | claimed |
| US-20100048579-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISTS | ARISTA LUCA | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048579-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISTS | GPBAR1, GPER1, ADRB1 | GRM4 244/4885LRRK2 2836/4885VCP 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.